ImCheck Receives FDA Fast Track Designation for ICT01 in …
WEBMarseille, France, September 18, 2024 – ImCheck Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ICT01 in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia (AML) patients 75 years or older, or who have comorbidities that preclude use of standard intensive induction chemotherapy.
Transplantation and long-term overall survival in acute myeloid ...
WEB2 days ago · Two thirds of patients with acute myeloid leukaemia are older than 60 years and have poor long-term survival. Although new front-line therapies, such as venetoclax-based regimens,1,2 CPX-351,3 targeted inhibitors,4,5 and maintenance therapy,6 have improved outcomes in older patients, effective long-term cures remain elusive. Allogeneic haematopoietic stem-cell transplantation (HSCT) has become ...
FDA Grants Fast Track Designation to ICT01 in Combination With ...
WEB5 days ago · ICT01 (ImCheck) in combination with azacitidine (Vidaza; Bristol-Myers) and venetoclax (Venclexta; AbbVie Inc) has been granted a fast track designation for the treatment of patients with acute myeloid leukemia (AML) 75 years or older who have comorbidities that prevent use of standard intensive induction chemotherapy.
Revumenib Shows Promise for Advanced Acute Myeloid Leukemia
WEBApr 18, 2023 · A new type of targeted therapy shows promise for acute myeloid leukemia (AML), one of the most difficult leukemias to treat. The drug, revumenib, is part of a group, or class, of drugs known as menin inhibitors.
Latest advancements in treatment for acute myeloid leukemia
WEBMar 2, 2023 · Acute myeloid leukemia, also called acute myelogenous leukemia (AML), is the most common type of acute leukemia in adults, and it can progress quickly if not treated. Chemotherapy can sometimes successfully treat AML, but new treatments and tailored chemotherapy approaches are helping even more people achieve remission.
New combinations and targeted therapies for acute myeloid leukemia …
WEBDec 11, 2023 · Acute myeloid leukemia is a cancer characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood-cell production. It's one of...
New CAR T Cell Clinical Trial for Acute Myeloid Leukemia Is First …
WEBApr 22, 2024 · Acute myeloid leukemia (AML) is one of the most challenging blood cancers. The disease moves quickly and needs aggressive treatment with chemotherapy, sometimes followed by a bone marrow transplant. Even when the first round of therapy works, AML often returns. Now a clinical trial at Memorial Sloan …
FDA Approves New Targeted Treatment for Acute Myeloid Leukemia
WEBRye Brook, N.Y., July 25, 2023 – The U.S. Food and Drug Administration (FDA) last week approved quizartinib (Vanflyta®) in combination with standard chemotherapies for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that carries a genetic mutation called FLT3-ITD.
Recommendations from the AML molecular MRD expert advisory …
WEBMay 23, 2024 · The standard-of-care treatment for patients with acute myeloid leukemia (AML) is being challenged by new classes of targeted therapies, including FLT3, IDH and BCL2 inhibitors [1].
Acute myeloid leukemia: current progress and future directions
WEBFeb 22, 2021 · Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
Skip to content